Clinical Case Reports and Studies
2026 Volume 12, Issue 5
DOI: 10.59657/2837-2565.brs.26.328

BioRes Scientia
Value your Research

Review Article

Open Access

Organoids at The Interface of Development and Clinic

Swarup K. Chakrabarti *

H. P. Ghosh Research Center, New Town, Kolkata, West Bengal 700161, India.

**Corresponding author: Swarup K. Chakrabarti.*

Abstract

Human organoids have emerged as transformative tools in biomedical research, bridging conventional cell lines and animal models through their ability to recapitulate human tissue architecture, function, and disease mechanisms. They enable the investigation of development, disease modeling, drug testing, infectious diseases, and regenerative medicine with enhanced physiological relevance. Recent advances in complementary technologies—including CRISPR-based genome editing, single-cell omics, organ-on-chip systems, and artificial intelligence—have further expanded the capabilities of organoid platforms, while ethical and regulatory frameworks continue to evolve. Looking ahead, the integration of quantum biology with organoid research may provide new insights into the fundamental mechanisms governing cellular processes and open novel avenues for translating human biology into clinical applications.

Keywords: human organoids; disease modeling; regenerative medicine; CRISPR; organoid-on-chip

Introduction

The development of human organoids is considered one of the most important advances in modern biomedical research [1]. Treatments tested in rodent models usually result in different outcomes in humans, which wastes resources and does not translate into effective patient care [2]. While cell lines are easy to use and inexpensive, the simple two-dimensional (2D) structure of cell lines cannot mimic the complex three-dimensional (3D) micro-environments and dynamic cell-cell interactions that occur in real tissues [3]. These constraints can lead to the loss of key attributes of cellular behavior and heterogeneity, as well as other in vivo features. On the other hand, animal models, while more physiologically relevant, have significant limitations based on species differences, confounding factors, and pragmatic issues that limit their predictive capabilities for human health [4]. Historically, most models-such as mice, which are genetically identical-do not allow for inter-individual variability, limiting their translational relevance [5]. Organoids, which are tiny 3D structures developed from pluripotent or adult stem cells, alleviate many of these constraints; organoids can self-organize and resemble the architecture and function of various human organs [1,6]. Organoids have been established as culture systems for several tissues, including brain, lung, heart, liver, and kidney organoids. Organoids were first developed to study how tissues and organs form, but they have quickly evolved into versatile models that better reflect human biology. They now offer powerful ways to study development, disease, and treatment responses in a setting closer to real human physiology [1,6-8].

Organoid Technology and Developmental Progression

Organoid technology has developed in several major steps. In 1981, pluripotent stem cells were established from mouse embryos, giving us the first essential tool for modeling tissues in culture [9]. Early efforts to grow and differentiate stem cells from other species provided the initial foundation for studying development in culture. The generation of human-induced pluripotent stem cells (iPSCs) in 2006 opened the way for patient-specific models, which were a pivotal step in progressing biomedical research [10]. Organoid technology then progressed rapidly, starting with intestinal (2009), gastric (2010), brain and liver (2013), kidney and lung (2014), and mammary, fallopian tube, and hippocampal organoids (2015) [11,12]. More recently, skin (2020) and lacrimal gland (2021) organoids have been generated, advancing disease modeling, drug testing, fetal organoids, and genetically engineered organoids (2022-2025) [13,14]. Together, these advances demonstrate the ability of organoids to recapture human development, disease, and aging in physiologically relevant systems.

Organoids as Functional Models of Human Development and Disease

Organoids mirror human development at structural and functional levels. Given the proper biochemical or mechanical cues, pluripotent or adult stem cells can differentiate, self-assemble, and make tissue-like structures that are analogous to early organogenesis [15,16]. Brain, gut, liver, kidney, and heart organoids are presented as living human development models, allowing researchers to study lineage commitment, morphogenesis, and tissue patterning in real time [17,18]. These models reproduce human-specific biological features that animal models cannot mimic. For example, brain organoids have provided insights into cortical development and neuron differentiation, while intestinal organoids have contributed to understanding epithelial turnover, stem cell maintenance, and regeneration [19,20]. Importantly, patient-derived or disease-specific organoids recapitulate disease processes accurately and represent platforms that can be used to study the molecular basis of disease [21,22]. Furthermore, assembloids, combinations of organoids from different organs, enable researchers to study how organs communicate and send signals to each other during development and disease [23].

In addition to developmental modeling, organoids play a pivotal role in studying human diseases. Cancer organoids preserve the genetic and epigenetic features of their corresponding tumors and serve as individualized models for testing drug efficacy and identifying targeted therapies [24]. Emerging systems, such as advanced co-cultures and organoid-on-chip (OoC) models, can now include stromal and immune components to partially recreate the tumor microenvironment (TME) and study immune cell responses [25]. Similarly, intestinal organoids from patients with cystic fibrosis (CF) have been used to test CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulators, providing results that directly guide patient treatment [26]. In this manner, a feedback loop of inquiry is established whereby knowledge generated in the laboratory environment can inform care for the patient.

Organoids can also be considered invaluable for infectious disease modeling. During the Zika virus outbreak, brain organoids illustrated the effect of viral infection of neural progenitors on proliferation leading to microcephaly [27]. More recently, lung and intestinal organoids have illuminated cellular entry, replication, and host response to infection with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) during COVID-19 [28,29]. In addition to modeling infections, lung organoids may provide insight into why some individuals experience a severe disease response while others are asymptomatic, thus suggesting potential mechanistic underpinnings of variation between individuals.

Clinical Translation and Technological Integration of Organoids

In the fields of translational and regenerative research, organoids have been integrated into preclinical drug discovery pipelines, as well as preclinical toxicity evaluation and pharmacogenomic profiling [30]. Organoid biobanks consisting of patient-derived samples, genetically diverse backgrounds, and disease states have allowed systematic drug screening and biomarker discovery while maintaining patient-specific characteristics [31]. In association with OoC technologies and microfluidic systems, organoids are able to recreate physiologically relevant microenvironments and interactions between organs [32]. Longitudinal biobanking of organoids sourced from a single patient allows normal organoids to act as internal controls for tracking pathological changes and also to track therapeutic responses [33].

Organoids also possess significant regenerative potential. There have been various studies demonstrating the successful transplantation of retinal, liver, intestinal, and pancreatic organoids in animal models that resulted in functional integration and some restoration of function in the tissue [34,35]. For example, in 2022 a group in Japan re-cultured intestinal organoids that had been developed from healthy mucosal stem cells from patients with ulcerative colitis for autologous transplantation [36]. Likewise, engineered bile duct organoids have appeared to have some application for recreation of the extrahepatic bile duct tree, including gallbladder wall and bile duct epithelium repair [37, 38]. Despite the aforementioned advances, challenges remain, including vascularization, immune compatibility, long-term compatibility, functionality, and regulatory compliance for use [39]. However, advances in tissue engineering, biomaterials, and transplantation immunology suggest that we are close to readying organoid-based regenerative therapies for clinical uses.

The fast progress of organoid study has been accelerated through the application of complementary technologies. The use of single-cell omics (SCO), CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome

editing, spatial transcriptomics (ST), and artificial intelligence (AI) can impact the derivation, alteration, and analysis of organoids [40,41]. CRISPR allows for precise genome editing to replicate heritable diseases or to correct mutations in organoids derived from patients [42]. AI-driven imaging and analytics improve the resolution of analyses focused on morphogenesis, differentiation, and drug responses. Bioengineering approaches, including three-dimensional bioprinting and biomimetic scaffolding, improve structural fidelity, and multi-organ-on-chip (MOC) systems also enable modeling of systemic physiology [43,44].

Navigating Ethics and Translation in Organoid Research

With organoids presenting ever-increasing complexity, ethical and regulatory issues are more pronounced. For example, brain organoids raise uncharted questions regarding consciousness and moral status, and human-animal chimeras further disrupt established lines of demarcation [45]. Regulators will need to determine whether organoids should be categorized as research tools, therapeutic modalities, or transitional structures. Commitment to fair access, transparency, and public engagement will be essential to reflect a moral obligation to yield the maximum benefits to our societies [46,47]. In short, organoids are a remarkable fusion of biological science and technology. They recapitulate development, model disease, and represent translational platforms that have the potential to transform health management. Although standardization, clinical integration, scalability, and ethical issues are daunting, they can ultimately be resolved. The transformative promise of organoids originates not just from their fidelity to biological material but from their conceptual integrity-each providing a framework that challenges conventional approaches to modeling human life. From scientific curiosity to clinical application, organoids are positioned at the intersection of biology, engineering, ethics, and medicine, providing an exciting framework for understanding, safeguarding, and improving human health.

Future Perspectives: Quantum Biology in Organoid Research

Going forward, the integration of quantum biology knowledge into organoid research may provide exciting new avenues to pursue. For the first time, organoids with improved physiological relevance and predictive outcomes could be used to study how quantum biological processes influence key cellular activities—energy transfer, signal transduction, and metabolism [48,49]. Combined with high-resolution, non-invasive monitoring, this approach may uncover mechanisms that connect organoid behavior to biological understanding and help translate that knowledge into practical applications. Adopting quantum-informed perspectives may offer innovative ways to investigate complex biological processes that remain obscure under traditional approaches.

Conclusion

Organoids have emerged as a powerful platform bridging traditional in vitro systems and in vivo models by recapitulating key aspects of human tissue structure, function, and disease. They enable more physiologically relevant studies across development, disease modeling, drug discovery, and precision medicine, particularly when combined with patient-derived systems and biobanking strategies. Integration with technologies such as CRISPR, single-cell and spatial omics, artificial intelligence, and organ-on-chip systems has further enhanced their utility and translational potential. While challenges remain in vascularization, scalability, standardization, immune compatibility, and regulatory approval, ongoing advances in bioengineering and regenerative medicine continue to address these limitations. As organoid systems evolve, careful consideration of ethical and regulatory frameworks will be essential to guide responsible development and clinical translation, positioning organoids as a rapidly advancing platform with the potential to transform biomedical research and therapeutic innovation.

Declarations

Conflict of Interest

The author does have anything to declare.

Funding

This research is supported by Bandhan, Kolkata, India.

Generative AI statement

The authors confirm that no content in this manuscript was generated by artificial intelligence (AI) tools without appropriate oversight. Any use of AI-assisted technologies (e.g., for language editing or formatting) has been transparently acknowledged, and the authors have reviewed and verified all content for accuracy, originality, and compliance with ethical

standards. The authors take full responsibility for the work, including any errors or inaccuracies.

References

1. Zhu Z, Cheng Y, Liu X, Ding W, Liu J. (2025). Advances in the Development and Application of Human Organoids: Techniques, Applications, and Future Perspectives. 34:9636897241303271.
2. Vandamme TF. (2014). Use of rodents as models of human diseases. *J Pharm Bioallied Sci*. 6(1):2-9.
3. Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, et al. (2018). 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. *Arch Med*. 14(4):910-919.
4. Frühwein H, Paul NW. (2025). "Lost in translation?" Animal research in the era of precision medicine. *J Transl Med*. 23(1):152.
5. Löscher W. (2024). Of Mice and Men: The Inter-individual Variability of the Brain's Response to Drugs. *eNeuro*. 11(2):0518-23.2024.
6. Yang S, Hu H, Kung H, Zou R, Dai Y, et al. (2023). Organoids: The current status and biomedical applications. 4(3):e274.
7. Kim J, Koo BK, Knoblich JA. (2020). Human organoids: model systems for human biology and medicine. *Nat Rev Mol Cell Biol*. 21(10):571-584.
8. Yao Q, Cheng S, Pan Q, Yu J, Cao G, et al. (2024). Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine. 5(10):e735.
9. Evans MJ, Kaufman MH. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature*. 292(5819):154-156.
10. Shi Y, Inoue H, Wu JC, Yamanaka S. (2017). Induced pluripotent stem cell technology: a decade of progress. *Nat Rev Dr Dis*. 16(2):115-130.
11. Corrò C, Novellasdemunt L, Li VSW. (2020). A brief history of organoids. *Am J Physiol Cell Physiol*. 319(1):C151-C165.
12. He J, Zhang X, Xia X, Han M, Li F, et al. (2020). Organoid technology for tissue engineering. *J Mol Cell Biol*. 12(8):569-579.
13. Lee J, Koehler KR. (2021). Skin organoids: A new human model for developmental and translational research. *Exp Derma*. 30(4):613-620.
14. Zeng D, Li S, Du F, Xia Y, Zhang J, et al. (2025). Advances in engineered organoid models of skin for biomedical research. *Burns Trauma*.
15. Poliwoda S, Noor N, Downs E, Schaaf A, Cantwell A, et al. (2022). Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice. 14(3):37498.
16. Li Y, Xu C, Ma T. (2014). In vitro organogenesis from pluripotent stem cells. 10(2):159-163.
17. Liu K, Chen X, Fan Z, Ren F, Liu J, et al. (2025). From organoids to organoids-on-a-chip: Current applications and challenges in biomedical research. *Chin Med J (Engl)*. 138(7):792-807.
18. Tang XY, Wu S, Wang D, Chu C, Hong Y, et al. (2022). Human organoids in basic research and clinical applications. *Sig Transd Tar The*. 7(1):168.
19. Xu J, Wen Z. (2021). Brain Organoids: Studying Human Brain Development and Diseases in a Dish. *Stem Cells Int*. 2021:5902824.
20. Hongxi W, Ruting W, Yiyang L, Qinglian H, Jibing C, et al. (2025). Human Brain Organoids: Development and Applications. 35:e2411040.
21. Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, et al. (2025). Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy. *Transl Oncol*. 51:102226.
22. Di Paola FJ, Calafato G, Piccaluga PP, Tallini G, Rhoden KJ. (2025). Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives. *J Pers Med*. 15(8):394.
23. Ouaidat S, Bellapianta A, Ammer-Pickhardt F, Taghipour T, Bolz M, et al. (2025). Exploring organoid and assembloid technologies: a focus on retina and brain. *Expert Rev Mol Med*. 27:e14.
24. Xin-Yi J, Yan-Ran W, Pin-Ru D, Shi-Yi Q, Hai-Tao J. (2025). Organoids in cancer therapies: a comprehensive review. *Fron Bioen Biotec*. 13:1607488.
25. Magré L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, et al. (2023). Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. 11(5):e006290.
26. Rodriguez Mier N, Destoop M, Spelier S, Ramalho AS, Beekman JM, et al. (2025). The Promising Role of Intestinal Organoids in the Diagnostic Work-Up of Cystic Fibrosis Screen Positive Inconclusive Diagnosis/CFTR-Related Metabolic Syndrome. 11(3):52.
27. Qian X, Nguyen HN, Jacob F, Song H, Ming GL. (2017). Using brain organoids to understand Zika virus-induced microcephaly. 144(6):952-957.
28. An Y, He Y, Ge N, Guo J, Yang F. (2023). Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives. 14(5):1677-1699.

29. van der Vaart J, Lamers MM, Haagmans BL, Clevers H. (2021). Advancing lung organoids for COVID-19 research. *Dis Model M*. 14(6):049060.
30. Singh D, Thakur A, Rakesh, Kumar A. (2025). Advancements in Organoid-Based Drug Discovery: Revolutionizing Precision Medicine and Pharmacology. *Drug Dev Res*. 86(4):e70121.
31. Botti G, Di Bonito M, Cantile M. (2021). Organoid biobanks as a new tool for pre-clinical validation of candidate drug efficacy and safety. *Int J Physiol Pathophysiol Pharmacol*. 13(1):17-21.
32. Papamichail L, Koch LS, Veerman D, Broersen K, van der Meer AD. (2025). Organoids-on-a-chip: microfluidic technology enables culture of organoids with enhanced tissue function and potential for disease modeling. 13:1515340.
33. Di Paola FJ, Calafato G, Piccaluga PP, Tallini G, Rhoden KJ. (2025). Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives. *J Pers Med*. 15(8):394.
34. Yu B, Zhou D, Wang F, Chen X, Li M, et al. (2025). Organoids for tissue repair and regeneration. *Mater Today Bio*. 33:102013.
35. Kim Y, Kang M, Mamo MG, Adisasmita M, Huch M. (2025). Liver organoids: Current advances and future applications for hepatology. 31(S):327-348.
36. Hammerhøj A, Chakravarti D, Sato T, Jensen KB, Nielsen OH. (2024). Organoids as regenerative medicine for inflammatory bowel disease. *iScience*. 27(6):110118.
37. Dutta A, Chowdhury N, Chandra S, Guha P, Saha V, et al. (2025). Gallbladder cholangiocyte organoids. *Biol Cell*. 117(2):e2400132.
38. Li P, Huang D, Gu W, Gao Y, Huang Y. (2025). Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction. *JGH Open*. 9(8):e70254.
39. Fan X, Hou K, Liu G, Shi R, Wang W, et al. (2025). Strategies to overcome the limitations of current organoid technology - engineered organoids. *J Tissue Eng*. 16:20417314251319475.
40. Menon AV, Song B, Chao L, Sriram D, Chansky P, et al. (2025). Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology. *Front Genome Ed*. 7:1565387.
41. Kim MG, Go MJ, Kang SH, Jeong SH, Lim K. (2025). Revolutionizing CRISPR technology with artificial intelligence. *Exp Mol*. 57(7):1419-1431.
42. Kolanu ND. (2024). CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. *Glob Med Genet*. 11(1):113-122.
43. Tripathi S, Mandal SS, Bauri S, Maiti P. (2022). 3D bioprinting and its innovative approach for biomedical applications. 4(1):e194.
44. Bao W, Liu J, Du C, Liu S, Liu J, et al. (2025). The role of 3D printing in skeletal muscle-on-a-chip models: Current applications and future potential. *Mater Today Bio*. 34:102222.
45. Jeziorski J, Brandt R, Evans JH, Campana W, Kalichman M, et al. (2023). Brain organoids, consciousness, ethics and moral status. *Semin Cell Dev Biol*. 144:97-102.
46. De Jongh, D., Massey, E. K., Bunnik, E. M. (2022). Organoids: a systematic review of ethical issues. *Stem Cell Research & Therapy*, 13(1):337.
47. Zhou LB, Lei YT, Han XX. (2025). Charting bioethical frontiers: China's human organoid guidelines in a global context. 12(1):64.
48. Smirnova L, Morales Pantoja IE, Hartung T. (2023). Organoid intelligence (OI) - The ultimate functionality of a brain microphysiological system. *ALTEX*. 40(2):191-203.
49. Morales Pantoja IE, Smirnova L, Muotri AR, Wahlin KJ, Kahn J, et al. (2023). First Organoid Intelligence (OI) workshop to form an OI community. *Front Artif Intell*. 6:1116870.
50. Pal S, Bhattacharya M, Lee SS, Chakraborty C. (2024). Quantum Computing in the Next-Generation Computational Biology Landscape: From Protein Folding to Molecular Dynamics. *Mol Biotechnol*. 66(2):163-178.

Cite this article: Chakrabarti SK. (2026). Organoids at The Interface of Development and Clinic, *Clinical Case Reports and Studies*, BioRes Scientia Publishers. 12(5):1-5. DOI: 10.59657/2837-2565.brs.26.328

Article History: **Received:** April 25, 2026 | **Accepted:** May 09, 2026 | **Published:** May 16, 2026